Trevi Therapeutics Inc (TRVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has a cash flow conversion efficiency ratio of -0.097x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.69 Million) by net assets ($172.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TRVI net asset quality score to measure how much of total assets are equity-financed.
Trevi Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Trevi Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Trevi Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Trevi Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevi Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Epoxy Base Electronic Material Corp Ltd
SHG:603002
|
0.002x |
|
Vietnam Airlines JSC
VN:HVN
|
-0.690x |
|
Shandong Linglong Tyre Co Ltd
SHG:601966
|
0.058x |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
0.042x |
|
BioArctic AB (publ)
ST:BIOA-B
|
-0.021x |
|
SBT Ultrasonic Technology Co. Ltd. A
SHG:688392
|
N/A |
|
Embotelladora Andina S.A
F:AKOB
|
0.129x |
|
BRP Inc
TO:DOO
|
0.634x |
Annual Cash Flow Conversion Efficiency for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Trevi Therapeutics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Trevi Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $183.24 Million | $-42.09 Million | -0.230x | +40.17% |
| 2024-12-31 | $99.64 Million | $-38.26 Million | -0.384x | +0.06% |
| 2023-12-31 | $82.55 Million | $-31.71 Million | -0.384x | -46.51% |
| 2022-12-31 | $107.46 Million | $-28.18 Million | -0.262x | +84.53% |
| 2021-12-31 | $17.07 Million | $-28.95 Million | -1.695x | -59.48% |
| 2020-12-31 | $27.28 Million | $-29.00 Million | -1.063x | -151.07% |
| 2019-12-31 | $54.55 Million | $-23.09 Million | -0.423x | +59.94% |
| 2018-12-31 | $17.31 Million | $-18.29 Million | -1.057x | -95.84% |
| 2017-12-31 | $14.78 Million | $-7.97 Million | -0.540x | -183.95% |
| 2016-12-31 | $-17.41 Million | $-11.19 Million | 0.643x | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more